 |
 |
Subject: Re: Permax I will ask the Permax team to respond to your question. Simply, pergolide is off patent in most global markets. Part of the reason the costs may seem relatively high are the associated manufacturing costs which exceed the Lilly norm. Future directions in Parkinson's research rest in early phase clinical development and encompass a new platform approach based on the so-called "excitatory amino acids" in brain. Good luck. Note: Mr. Tollefson is the Director of Neurosciences at Eli Lilly